IN2014MN01839A - - Google Patents

Info

Publication number
IN2014MN01839A
IN2014MN01839A IN1839MUN2014A IN2014MN01839A IN 2014MN01839 A IN2014MN01839 A IN 2014MN01839A IN 1839MUN2014 A IN1839MUN2014 A IN 1839MUN2014A IN 2014MN01839 A IN2014MN01839 A IN 2014MN01839A
Authority
IN
India
Prior art keywords
compounds
formula
relates
oxides
diseases
Prior art date
Application number
Other languages
English (en)
Inventor
Sanjay Kumar
Rajiv Sharma
Vishal Ashok Mahajan
Sangameshwar Prabhakar Sawargave
Original Assignee
Piramal Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Entpr Ltd filed Critical Piramal Entpr Ltd
Publication of IN2014MN01839A publication Critical patent/IN2014MN01839A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/06—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C07D307/08—Preparation of tetrahydrofuran
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Epoxy Compounds (AREA)
IN1839MUN2014 2012-02-28 2013-02-27 IN2014MN01839A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261603988P 2012-02-28 2012-02-28
US201261736622P 2012-12-13 2012-12-13
PCT/IB2013/051555 WO2013128378A1 (en) 2012-02-28 2013-02-27 Phenyl alkanoic acid derivatives as gpr agonists

Publications (1)

Publication Number Publication Date
IN2014MN01839A true IN2014MN01839A (ja) 2015-07-03

Family

ID=48225087

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1839MUN2014 IN2014MN01839A (ja) 2012-02-28 2013-02-27

Country Status (16)

Country Link
US (1) US20150072969A1 (ja)
EP (1) EP2820005A1 (ja)
JP (1) JP2015508809A (ja)
KR (1) KR20140138243A (ja)
CN (1) CN104144920A (ja)
AR (1) AR090191A1 (ja)
AU (1) AU2013227266A1 (ja)
CA (1) CA2866210A1 (ja)
IL (1) IL234254A (ja)
IN (1) IN2014MN01839A (ja)
MX (1) MX2014010272A (ja)
NZ (1) NZ631569A (ja)
RU (1) RU2014138894A (ja)
TW (1) TW201341356A (ja)
WO (1) WO2013128378A1 (ja)
ZA (1) ZA201407034B (ja)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014005935A2 (pt) 2011-09-16 2017-03-28 Fovea Pharmaceuticals derivados de anilina, sua preparação e sua aplicação terapêutica
WO2015028960A1 (en) * 2013-08-28 2015-03-05 Piramal Enterprises Limited Substituted heterocyclic derivatives as gpr agonists and uses thereof
EA201690888A1 (ru) 2013-11-14 2016-10-31 Кадила Хелзкэр Лимитед Новые гетероциклические соединения
US9957219B2 (en) 2013-12-04 2018-05-01 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
EP3102198B1 (en) 2014-02-06 2020-08-26 Merck Sharp & Dohme Corp. Antidiabetic compounds
CA2935897C (en) 2014-02-19 2018-07-03 Piramal Enterprises Limited Compounds for use as gpr120 agonists
AU2015293541B2 (en) 2014-07-25 2019-11-21 Piramal Enterprises Limited Substituted phenyl alkanoic acid compounds as GPR120 agonists and uses thereof
US10100042B2 (en) 2014-08-08 2018-10-16 Merck Sharp & Dohme Corp. [5,6]—fused bicyclic antidiabetic compounds
EP3177287B1 (en) 2014-08-08 2022-02-23 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US10662171B2 (en) 2014-08-08 2020-05-26 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2016019587A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [7, 6]-fused bicyclic antidiabetic compounds
WO2016032120A1 (ko) * 2014-08-27 2016-03-03 씨제이헬스케어 주식회사 신규한 아미노-페닐-설포닐-아세테이트 유도체 및 이의 용도
KR101641023B1 (ko) 2014-08-27 2016-07-20 씨제이헬스케어 주식회사 신규한 아미노-페닐-설포닐-아세테이트 유도체 및 이의 용도
AU2015313829B2 (en) 2014-09-11 2020-07-23 Piramal Enterprises Limited Fused heterocyclic compounds as GPR120 agonists
FI3737470T3 (fi) 2018-01-08 2023-03-19 Celon Pharma Sa 3-fenyyli-4-heksyylihappojohdannaisia GPR40-agonisteina
TWI796596B (zh) 2018-02-13 2023-03-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
CN112399874B (zh) 2018-07-13 2024-03-22 吉利德科学公司 Pd-1/pd-l1抑制剂
CN112955435A (zh) 2018-10-24 2021-06-11 吉利德科学公司 Pd-1/pd-l1抑制剂
EP4041722A4 (en) 2019-10-07 2023-12-13 Kallyope, Inc. GPR119 AGONISTS
KR20230012597A (ko) 2020-05-19 2023-01-26 칼리오페, 인크. Ampk 활성화제
AU2021297323A1 (en) 2020-06-26 2023-02-16 Kallyope, Inc. AMPK activators

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3400392B2 (ja) * 1994-10-18 2003-04-28 ファイザー製薬株式会社 ５−リポキシゲナーゼ阻害剤及び新規医薬組成物
US5883106A (en) * 1994-10-18 1999-03-16 Pfizer Inc. 5-lipoxygenase inhibitors
SK281577B6 (sk) * 1994-10-18 2001-05-10 Pfizer Inc. Heterocyklické zlúčeniny a farmaceutický prostriedok na ich báze
US6403632B1 (en) * 2000-03-01 2002-06-11 Bristol Myers Squibb Pharma Co Lactam metalloprotease inhibitors
MXPA02005982A (es) * 1999-12-17 2003-01-28 Abbott Lab Inhibodres de expresion del gen de interleucina 5.
GB0214149D0 (en) 2002-06-19 2002-07-31 Glaxo Group Ltd Chemical compounds
US7102008B2 (en) * 2002-08-01 2006-09-05 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme
WO2005054213A1 (ja) * 2003-12-02 2005-06-16 Shionogi & Co., Ltd. ペルオキシソーム増殖活性化受容体アゴニスト活性を有するイソキサゾール誘導体
CN1946666A (zh) * 2004-02-27 2007-04-11 埃姆艮股份有限公司 用于治疗代谢性疾病的化合物、药物组合物和方法
EP1750727A2 (en) 2004-04-23 2007-02-14 Exelixis, Inc. Kinase modulators and methods of use
CA2626446A1 (en) * 2005-11-07 2007-05-18 Irm Llc Compounds and compositions as ppar modulators
MX2008014560A (es) * 2006-05-18 2008-11-28 Wellstat Therapeutics Corp Compuestos para el tratamiento de trastornos metabolicos.
CL2007001873A1 (es) 2006-06-27 2008-01-04 Takeda Pharmaceutical Acido((3s))-6-((¨2,6-dimetil-4-(3-(metilsulfonil)-propoxi)bifenil-3-il)metoxi-2,3-dihidro-1-benzofuran-3-il)acetico o una sal del mismo
TW200838526A (en) * 2006-12-01 2008-10-01 Astellas Pharma Inc Carboxylic acid derivatives
WO2009048527A1 (en) * 2007-10-10 2009-04-16 Amgen Inc. Substituted biphenyl gpr40 modulators
CN101945848A (zh) * 2007-12-20 2011-01-12 英维沃医药有限公司 四取代的苯
WO2009111056A1 (en) 2008-03-06 2009-09-11 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
EP2358656B1 (en) 2008-10-15 2014-01-01 Amgen, Inc Spirocyclic gpr40 modulators
WO2010048207A2 (en) * 2008-10-21 2010-04-29 Metabolex, Inc. Aryl gpr120 receptor agonists and uses thereof
DK2356113T3 (en) * 2008-11-14 2015-04-13 Bayer Ip Gmbh Heterocyclic SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS
EP2423176A4 (en) 2009-04-22 2012-11-07 Astellas Pharma Inc CARBOXYLIC ACID COMPOUND
WO2010138901A1 (en) * 2009-05-29 2010-12-02 Biogen Idec Ma Inc Carboxylic acid-containing compounds, derivatives thereof, and related methods of use
CA2767987A1 (en) * 2009-07-17 2011-01-20 Shire Llc Novel carbamate amino acid and peptide prodrugs of opioids and uses thereof
DE102009046115A1 (de) * 2009-10-28 2011-09-08 Bayer Schering Pharma Aktiengesellschaft Substituierte 3-Phenylpropansäuren und ihre Verwendung
WO2012011125A1 (en) 2010-07-23 2012-01-26 Connexios Life Sciences Pvt. Ltd. Agonists of gpr40
US9073895B2 (en) * 2010-12-16 2015-07-07 Boehringer Ingelheim International Gmbh Biarylamide inhibitors of leukotriene production

Also Published As

Publication number Publication date
ZA201407034B (en) 2017-08-30
JP2015508809A (ja) 2015-03-23
AU2013227266A1 (en) 2014-10-02
MX2014010272A (es) 2015-08-14
US20150072969A1 (en) 2015-03-12
TW201341356A (zh) 2013-10-16
WO2013128378A1 (en) 2013-09-06
RU2014138894A (ru) 2016-04-20
CN104144920A (zh) 2014-11-12
NZ631569A (en) 2016-10-28
IL234254A (en) 2017-03-30
KR20140138243A (ko) 2014-12-03
AR090191A1 (es) 2014-10-29
CA2866210A1 (en) 2013-09-06
EP2820005A1 (en) 2015-01-07

Similar Documents

Publication Publication Date Title
IN2014MN01839A (ja)
JO3781B1 (ar) مشتقات الكينولون
PH12014502524A1 (en) Carboxylic acid compounds
MX2010007683A (es) Derivados heterociclicos fusionados y metodos de uso como inhibidores de c-met.
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
BR112014002202A2 (pt) macrociclos como inibidores de fator xia
MX342212B (es) Inhibidores de neprilisina.
MX2012012225A (es) Profármacos de agentes tearapéuticos de liberación de óxido nítrico.
EA201270492A1 (ru) Соединения для лечения дислипидемии и связанных с ней заболеваний
IN2014MN00697A (ja)
WO2012116176A3 (en) Asymmetric ureas and medical uses thereof
EA201792071A3 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
WO2014170842A3 (en) Substituted alkyl carboxylic acid derivatives as gpr agonists
CR20130693A (es) Composición farmacéutica ortalmológica tópica que contiene regorafenib
IN2013DN02555A (ja)
IN2014KN01113A (ja)
MX2013003736A (es) Novedosos agonistas del receptor de la proteina g 119.
MX353991B (es) Agonista del receptor de 5-ht4 como agente procinetico.
IN2013MN00581A (ja)
PH12015502560A1 (en) Use of a thiazolo pyrimidinone for the treatment of inflammatory bowel disease
MY168750A (en) Cycloalkane carboxylic acid derivatives as cxcr3 receptor antagonists
MX2009013240A (es) Derivados de carboxamida heterociclicos, su uso farmaceutico y composiciones.
TN2013000052A1 (en) Oxadiazole inhibitors of leukotriene production
TN2010000318A1 (en) Fused heterocyclic derivatives and methods of use as c-met inhibitors
IN2013MU02366A (ja)